Resumen
Definición
Anamnesis y examen
Principales factores de diagnóstico
- crecimiento deficiente
- estatura baja
- desarrollo puberal retrasado/ausente
- amenorrea primaria
- defectos cardíacos congénitos
- alteraciones esqueléticas
- cuello alado
- linfedema periférico
Otros factores de diagnóstico
- rasgos dismórficos
- amenorrea secundaria
- múltiples nevos melanocíticos
- otitis media recurrente/grave
- chasquido o soplo sistólico eyectivo
- habilidades sociales deficientes
- alteraciones oculares
- hipertensión en extremidades superiores
- uñas hiperconvexas o distróficas
Pruebas diagnósticas
Pruebas diagnósticas que deben considerarse
- pruebas audiológicas
- examen oftalmológico
- edad ósea
- ecocardiograma
- imagen por resonancia magnética cardíaca
- hormona foliculoestimulante sérica y hormona antimülleriana
- examen del esqueleto
- ultrasonido pélvico
- ultrasonido renal
- pruebas de función tiroidea
- anticuerpos antitiroideos
- LFT/gamma glutamil transferasa/fosfatasa alcalina
- glucosa en ayunas y HbA1c
- lípidos séricos
- nivel de IgA e IgA transglutaminasa tisular
- niveles de la vitamina D
Algoritmo de tratamiento
Colaboradores
Autores
Patricia Y. Fechner, MD
Medical Director
Differences of Sex Development Program
Medical Director Congenital Adrenal Hyperplasia (CAH) Center of Excellence
Medical Co-Director Turner Syndrome Clinic
Seattle Children’s Hospital
Professor of Pediatrics
University of Washington
Seattle
WA
Divulgaciones
PYF is currently considering research using growth hormone in Turner syndrome sponsored by industry but no contract has been signed. She has been invited to participate in the 2023 updated Guidelines for Turner Syndrome in June 2023. She has also conducted contract research from Neurocrine BioSciences, Pfizer, Spruce Biosciences, and Ascendis Pharma. PYF has stock in Abbott Laboratories and AbbVie. She declares that these activities do not relate to the topic. PYF participated in Meet the Professor for the Endocrine Society 2019 Annual Meeting and is an author of references cited in this topic.
Agradecimientos
Dr Patricia Y. Fechner would like to gratefully acknowledge Dr Carolyn A. Bondy, a previous contributor to this topic.
Divulgaciones
CAB is an author of references cited in this topic.
Revisores por pares
Gerard Conway, MD
Consultant Endocrinologist
University College London Hospitals
London
UK
Divulgaciones
GC declares that he has no competing interests.
Peter Hindmarsh, MD
Professor
Developmental Endocrinology Research Unit
Institute of Child Health
London
UK
Divulgaciones
PH declares that he has no competing interests.
Vaneeta Bamba, MD
Associate Professor of Pediatrics
Children’s Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania
Philadelphia
PA
Divulgaciones
VB declares that in Nov 2020, she was part of a Genetic Short Stature Advisory Board sponsored by NovoNordisk. VB is a member of the Turner Syndrome Society Scientific Advisory Board- this is not compensated. VB has no known upcoming financial interests or relationships.
Agradecimiento de los revisores por pares
Los temas de BMJ Best Practice se actualizan de forma continua de acuerdo con los desarrollos en la evidencia y en las guías. Los revisores por pares listados aquí han revisado el contenido al menos una vez durante la historia del tema.
Divulgaciones
Las afiliaciones y divulgaciones de los revisores por pares se refieren al momento de la revisión.
Referencias
Artículos principales
Gravholt CH, Andersen NH, Conway GS, et al. Clinical practice guidelines for the care of girls and women with Turner syndrome: proceedings from the 2016 Cincinnati International Turner Syndrome Meeting. Eur J Endocrinol. 2017 Sep;177(3):G1-G70.Texto completo Resumen
Bondy CA. Heart disease in Turner syndrome. Minerva Endocrinol. 2007;32:245-261. Resumen
Silberbach M, Roos-Hesselink JW, Andersen NH, et al. Cardiovascular health in Turner syndrome: a scientific statement from the American Heart Association. Circ Genom Precis Med. 2018 Oct;11(10):e000048.Texto completo Resumen
Canadian Growth Hormone Advisory Committee. Impact of growth hormone supplementation on adult height in Turner syndrome: results of the Canadian randomized controlled trial. J Clin Endocrinol Metab. 2005;90:3360-3366.Texto completo Resumen
Matura LA, Ho VB, Rosing DR, et al. Aortic dilatation and dissection in Turner syndrome. Circulation. 2007;116:1663-1670.Texto completo Resumen
Artículos de referencia
Una lista completa de las fuentes a las que se hace referencia en este tema está disponible aquí.
El uso de este contenido está sujeto a nuestra cláusula de exención de responsabilidad